GLP-1 Receptor Agonists (Class Overview)
Generic name: Semaglutide / Liraglutide / Tirzepatide* | Common brands: Ozempic, Wegovy, Rybelsus, Saxenda, Mounjaro*
Why this class
- Improves glucose with low hypoglycemia risk and substantial weight loss benefits; some agents reduce major CV events in T2DM.
- Slows gastric emptying and increases satiety, aiding calorie control.
Dosing & titration
- Start low, titrate every 2–4 weeks to reduce GI effects; injectable weekly (semaglutide/tirzepatide) or daily (liraglutide); oral semaglutide requires empty stomach + water.
Monitoring & safety
- Track weight, HbA1c, renal function if nausea/vomiting risk dehydration.
- Common: nausea, fullness, constipation; usually transient. Rare: pancreatitis, gallbladder issues—seek care for severe abdominal pain.
- Avoid in personal/family history of medullary thyroid carcinoma or MEN2 (per label).
Pairing with other meds
- If combined with insulin or sulfonylureas, consider dose reduction to avoid hypoglycemia.
Related drug cards
- Semaglutide (weight & diabetes)
Medical Disclaimer: Education only; not medical advice.
*Tirzepatide is technically dual GIP/GLP-1 but often grouped here for patient education.
🧪 Key Lab Tests to Monitor
Doctors often track these specific indicators to ensure GLP-1 Receptor Agonists (Class Overview) is working safely and effectively:
Taking GLP-1 Receptor Agonists (Class Overview)?
Upload your blood test results. WellAlly will automatically plot your glucose trends alongside your medication timeline.
⚠️ Medical Disclaimer
The information provided here is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider regarding your medications and lab results. Do not stop taking any medication without talking to your doctor.